May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Anti-VEGF Therapy With Bevacizumab for Advanced Neovascular AMD
Author Affiliations & Notes
  • K. B. Schaal
    Department of Ophthalmology, University of Heidelberg, Heidelberg, Germany
  • C. Engler
    Department of Ophthalmology, University of Heidelberg, Heidelberg, Germany
  • D. Thiemeyer
    Department of Ophthalmology, University of Heidelberg, Heidelberg, Germany
  • S. Dithmar
    Department of Ophthalmology, University of Heidelberg, Heidelberg, Germany
  • Footnotes
    Commercial Relationships K.B. Schaal, None; C. Engler, None; D. Thiemeyer, None; S. Dithmar, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1782. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K. B. Schaal, C. Engler, D. Thiemeyer, S. Dithmar; Anti-VEGF Therapy With Bevacizumab for Advanced Neovascular AMD. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1782.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To evaluate the efficacy of bevacizumab (AvastinTM) in advanced neovascular age-related macular degeneration with best corrected visual acuity (BCVA) less than 20/200.

Methods:: Prospective study. After informed consent patients with advanced neovascular AMD and BCVA of 20/200 or worse receive intravitreal bevacizumab (1.25 mg/0.05ml) every 6 weeks until CNV-leakage resolves. Ophthalmic examination, visual acuity (ETDRS) and Stratus OCTTM are performed at baseline, 1 week after injection and on a monthly basis. Fluorescein angiography and regular medical check-up are also performed.

Results:: 13 patients have been included in the study so far with a mean follow-up of 12 ± 6 weeks. The intravitreous injections were very well tolerated with no intraocular or systemic adverse events. On last visit, mean central retinal thickness decreased by 251µm compared to baseline. Visual acuity could be stabilised in all patients. 46.5% of patients gained at least 3 lines. 8% of patients gained ≥ 6 lines.

Conclusions:: The intravitreal use of bevacizumab even for advanced neovascular AMD with low BCVA at baseline seems to be effective. Follow-up is ongoing to determine the durability of this favorable outcome.

Keywords: growth factors/growth factor receptors • age-related macular degeneration • choroid: neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×